Image modified: Verband Forschender Arzneimittelhersteller e.V.

Precision Medicine and Biopharmaceuticals Drive Innovation in Germany’s Medical Biotechnology Sector

Medical Biotechnology in Germany 2025 – Biopharmaceuticals and Precision Medicine as Innovation Drivers

Germany maintains its leading role in medical biotechnology. The new Biotech Report 2025 by the Boston Consulting Group and the German Association of Research-Based Pharmaceutical Companies (vfa) presents impressive figures. With a record revenue of €21.4 billion from biopharmaceuticals and a 35% market share, the sector is proving to be increasingly relevant – both economically and medically.

In 2024, 64% of all EU drug approvals were biopharmaceuticals, including 20 biosimilars and 18 original biologics. The spotlight is on precision medicine, with applications ranging from oncology to gene-based personalized therapies. The number of clinical-stage biopharmaceuticals continues to grow, now reaching 677 active drug candidates, with nearly two-thirds being recombinant antibodies – the backbone of development pipelines.

Precision medicine represents a paradigm shift in patient care: away from one-size-fits-all treatments and toward targeted and even individualized therapeutic strategies. Modern diagnostics and biomarkers enable tailored therapies – such as CAR-T cell therapies and mRNA-based cancer vaccines – customized for individual patients.

The industry is also expanding structurally: Over 52,000 employees are now working in the medical biotechnology sector – a new record. The biosimilars market continues to thrive, growing 11% to €2.8 billion in 2024 alone. In eligible segments, biosimilars now achieve up to 97% prescription share, demonstrating the effectiveness of current market competition.

Germany’s political framework is improving, with explicit support for precision medicine as a strategic competitive factor. The coalition agreement sends a strong political signal for innovation and healthcare progress.